Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Net Margin: 2013-2025

Historic Net Margin for Theravance Biopharma (TBPH) over the last 13 years, with Sep 2025 value amounting to 18.08%.

  • Theravance Biopharma's Net Margin rose 9336.00% to 18.08% in Q3 2025 from the same period last year, while for Sep 2025 it was 27.15%, marking a year-over-year increase of 10533.00%. This contributed to the annual value of -99.39% for FY2024, which is 328.00% down from last year.
  • Latest data reveals that Theravance Biopharma reported Net Margin of 18.08% as of Q3 2025, which was down 91.36% from 209.33% recorded in Q2 2025.
  • Over the past 5 years, Theravance Biopharma's Net Margin peaked at 7,445.92% during Q3 2022, and registered a low of -212.04% during Q1 2023.
  • Over the past 3 years, Theravance Biopharma's median Net Margin value was -80.42% (recorded in 2024), while the average stood at -62.43%.
  • Per our database at Business Quant, Theravance Biopharma's Net Margin spiked by 728,977bps in 2022 and then crashed by 750,295bps in 2023.
  • Over the past 5 years, Theravance Biopharma's Net Margin (Quarterly) stood at 172.49% in 2021, then plummeted by 14,591bps to 26.58% in 2022, then plummeted by 7,503bps to -48.45% in 2023, then tumbled by 7,473bps to -123.17% in 2024, then surged by 9,336bps to 18.08% in 2025.
  • Its Net Margin stands at 18.08% for Q3 2025, versus 209.33% for Q2 2025 and -87.98% for Q1 2025.